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Background: Guidelines recommend ideally 1 year of ADP receptor inhibitor (ADPri) therapy after acute myocardial infarction (AMI). We examined 
contemporary prevalence of early ADPri cessation in community practice.
methods: We examined ADPri use within 6 weeks following AMI and PCI in 7,887 patients treated at 215 hospitals from 4/2010 to 8/2012 in the 
TRANSLATE-ACS study. We used multivariable logistic regression to identify factors associated with early ADPri cessation.
results: Overall, 268 patients (3.4%) reported stopping their ADPri within 6 weeks post-AMI; 40% of these had received a drug eluting stent 
(DES). Patients with early cessation were less likely to be insured, married, or a high school graduate, and more likely to have depression and be 
newly prescribed ADPri, whereas age, sex, MI type, and type of ADPri used were similar between groups (Table). Thirty percent of patients with early 
cessation stopped drug without discussing with a doctor. Most common patient reported reasons for stopping ADPri include doctor felt drug no 
longer needed (30%), drug was too expensive (16%), or ran out of pills and did not refill (11%). Bleeding accounted for 4% of early cessation.
conclusion: While rates of early ADPri cessation are low in contemporary AMI patients, a substantial proportion of these had received DES and had 
not discussed this decision with their doctors. There remains room to improve ADPri-related patient education and adherence efforts in vulnerable 
populations.
 
